Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Abstract Background Fremanezumab has demonstrated to be effective, safe, and tolerated in the prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials (RCTs). Real-life studies are needed to explore drug effects in unselected patients in routine circumstances and to p...

Full description

Bibliographic Details
Main Authors: Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo FilippiBonassi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, for the FRIEND-Study Group
Format: Article
Language:English
Published: BMC 2022-04-01
Series:The Journal of Headache and Pain
Subjects:
Fremanezumab
Migraine treatment
CGRP monoclonal antibody
Real-world
Predictor
Online Access:https://doi.org/10.1186/s10194-022-01396-x

Internet

https://doi.org/10.1186/s10194-022-01396-x

Similar Items